Roche Holding AG
- Country
- ๐จ๐ญSwitzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) in Healthy Japanese Participants
- First Posted Date
- 2017-02-02
- Last Posted Date
- 2018-10-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT03040635
- Locations
- ๐บ๐ธ
Collaborative Neuroscience Network, Inc., Garden Grove, California, United States
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration
- Conditions
- Macular Degeneration, Age-RelatedNeovascularization, Choroidal
- Interventions
- First Posted Date
- 2017-02-01
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 76
- Registration Number
- NCT03038880
- Locations
- ๐บ๐ธ
Retinal Consultants of Arizona, Phoenix, Arizona, United States
๐บ๐ธCalifornia Retina Consultants, Bakersfield, California, United States
๐บ๐ธRand Eye, Deerfield Beach, Florida, United States
Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Drug: RO7239361Drug: Placebo for RO7239361
- First Posted Date
- 2017-02-01
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 166
- Registration Number
- NCT03039686
- Locations
- ๐บ๐ธ
University of Massachusetts Memorial Childrens Medical Center; Department of Neurology, Worcester, Massachusetts, United States
๐บ๐ธRush University Medical Center - PPDS, Chicago, Illinois, United States
๐บ๐ธNationwide Childrens Hospital; Research Institute at Nationwide Childrens Hospital, Columbus, Ohio, United States
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- Ovarian CancerFallopian Tube CancerPeritoneal Neoplasms
- Interventions
- First Posted Date
- 2017-01-31
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1301
- Registration Number
- NCT03038100
- Locations
- ๐บ๐ธ
Columbus NCORP, Columbus, Ohio, United States
๐บ๐ธOhio State University, Arthur James Cancer Hospital, Columbus, Ohio, United States
๐บ๐ธGreater Baltimore Medical Center, Baltimore, Maryland, United States
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of RO7062931in Healthy Volunteers and Subjects With Chronic Hepatitis B
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: RO7062931Drug: PlaceboDrug: Immune Modulator
- First Posted Date
- 2017-01-31
- Last Posted Date
- 2020-12-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 119
- Registration Number
- NCT03038113
- Locations
- ๐จ๐ณ
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan
๐จ๐ณTaipei Veterans General Hospital, Taipei City, Taiwan
๐จ๐ณChang Gung Medical Foundation Linkou Branch, Taoyuan City, Taiwan
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
- Conditions
- RET-altered Non Small Cell Lung CancerThyroid DiseasesThyroid NeoplasmThoracic NeoplasmsCarcinoma, BronchogenicHead and Neck NeoplasmsCarcinomaNeoplasms, Germ Cell and EmbryonalDigestive System NeoplasmCarcinoma, Neuroendocrine
- Interventions
- First Posted Date
- 2017-01-31
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 589
- Registration Number
- NCT03037385
- Locations
- ๐ฉ๐ช
Thoraxklinik Heidelberg gGmbH, Heidelberg, Germany
๐ณ๐ฑUniversitair Medisch Centrum Groningen, Groningen, Netherlands
๐บ๐ธMaryland Oncology Hematology, P.A., Columbia, Maryland, United States
A Study Investigating the Excretion Balance, Pharmacokinetics and Metabolism of a Single Oral Dose of [14C]-Labeled Risdiplam (RO7034067) in Healthy Male Participants
- Conditions
- Healthy
- Interventions
- Drug: [^14C]-Risdiplam
- First Posted Date
- 2017-01-30
- Last Posted Date
- 2018-10-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT03036501
- Locations
- ๐ณ๐ฑ
Pra International Group B.V, Groningen, Netherlands
A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 174
- Registration Number
- NCT03032172
- Locations
- ๐บ๐ธ
Columbia University Medical Center, New York, New York, United States
๐ซ๐ทHopital Femme Mere Enfant, Bron, France
๐ซ๐ทCHRU de Montpellier, Hopital Gui de Chauliac, Montpellier, France
A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
- First Posted Date
- 2017-01-19
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 778
- Registration Number
- NCT03024996
- Locations
- ๐บ๐ธ
University of Texas Southwestern Medical Center, Dallas, Texas, United States
๐จ๐ฆSunnybrook Odette Cancer Centre, Toronto, Ontario, Canada
๐จ๐ฆPrincess Margaret Cancer Center, Toronto, Ontario, Canada
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT03020160
- Locations
- ๐ฆ๐บ
Royal Brisbane Hospital; Clinical Haematology, Brisbane, Queensland, Australia
๐ฏ๐ตNational Center for Child Health and Development, Tokyo, Japan
๐บ๐ธUniversity of Michigan, C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States